AstraZeneca

Open: 65.46 Close: 65.35 Change: -0.11

6 risks of investing in AstraZeneca found by an AI after reading the whole internet.

Are looking for the most relevant information about AstraZeneca? Investor spend a lot of time searching for information to make investment decisions in AstraZeneca. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, development, US, UK, Astra, Zeneca, PLC, and the most common words in the summary are: astrazeneca, company, pharmaceutical, news, astrazenecas, vaccine, report, . One of the sentences in the summary was: Sweden was first country outside Europe to temporarily suspend use.. Other searches related to …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

AstraZeneca PLC ADR AZN, -1.48% inched 0.61% higher to $66.33 Tuesday. Sweden is latest country to pause use of AstraZecas COVID-19 vaccine. Sweden was first country outside Europe to temporarily suspend use.

Today's News

AstraZeneca PLC closed £22.12 short of its 52-week high (£123.92) on Wednesday. AstraZeneca PLC ADR AZN, -1.48% inched 0.61% higher to $66.33 Tuesday, on what proved to be an all-around mixed trading session for the stock market. The NASDAQ Composite Index COMP, -0.55% rising 0.37% to 16,035.30 and the Dow Jones Industrial Average DJIA fell 0.25%. AstraZeneca reports strong financial performance for FY 2023 with a 6% increase in total revenue, driven by double-digit growth in oncology, CVRM, R&I, and rare disease. SOPHiA GENETICS has expanded their HRD testing program in Spain to support the molecular diagnosis. Sweden is latest country to pause use of AstraZenecas COVID-19 vaccine as European regulators review safety data following reports of dangerous blood clots in some recipients. Thailand was the first country outside Europe to temporarily suspend use. Profund Advisors LLC raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 28.1% during the 3rd quarter. Phase 3 data for AstraZecas Fasenra published in NEJM. AstraZeneca announced plans for a major corporate restructuring in March 2013. Company announced closure of research and development activities at Alderley Park in Cheshire and Loughborough in the UK and at Lund in Sweden. AstraZeneca has its headquarters in Cambridge, United Kingdom, and main research and development (R&D) centres are in Cambridge (UK), Gaithersburg (Maryland, US), Gothenburg (Sweden) and Warsaw (Poland) In August 2012, Pascal Soriot was named CEO. AstraZeneca agreed to pay £505 million to settle a UK tax dispute related to transfer mispricing. In August 2020 Astra Zeneca declared towards the European Commission and the EU member states: 13.1 AstraZeneca underwrites Cambridge-Sweden flights. AstraZeneca Inks $1.8B in Immuno-Oncology deals as Q1 Profit Dips. For Up-to-$825M, Daiichi Sankyo Joins Astra Zeneca in Co-Marketing Movantik AstraZeneca is one of the top 10 pharmaceutical companies worldwide (based on Rx drug revenue) In 2023, Astra Zeneca spent some 10.9 billion U.S. dollars in research and development. AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases and BioPharmaceuticals. Based in Cambridge, UK, Astra Zeneca operates in over 100 countries. AstraZeneca revenue from 2006 to 2023 (in million U.S. dollars) Statista, Statista Inc., 20 Feb 2024, published: AstraZenecas Revenue from 2006-2023 Cellectis stock is taking off on Wednesday as investors in CLLS react to a massive $245 million investment. Astrazeneca acquires Gracell biotechnologies for $1.2 billion. The acquisition enriches AstraZenecas growing pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T-cell. AstraZeneca PLCs (AZN) American depositary receipts (ADRs) fell more than 4% Thursday after the drug maker reported its profit was hurt by falling demand for COVID-19 treatments. Deutsche Bank also cut its rating of the stock to Sell. AstraZeneca returns to FibroGen the Rights to Roxadustat in US, Other Territories 2/28/2024. AstraZeneca announced to build a new cell therapy discovery and development facility in Rockville, Maryland, US, to launch its life-saving cell therapy platforms in the US.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

How much time have you spent trying to decide whether investing in AstraZeneca? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, development, US, UK, Astra, Zeneca, PLC, and the most common words in the summary are: astrazeneca, company, pharmaceutical, news, astrazenecas, vaccine, report, . One of the sentences in the summary was: Sweden was first country outside Europe to temporarily suspend use.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #company #pharmaceutical #news #astrazenecas #vaccine #report.